Wedbush Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $52

Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc.

EWTX

0.00

Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ: EWTX) with a Outperform and raises the price target from $46 to $52.